Schedule 13D ownership disclosure

WEREWOLF THERAPEUTICS INC

Common Stock · CUSIP: 95075A107

Event date: 2025-11-13

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • MPM BioVentures 2014, L.P.Reported CIK 0001609492

    Shares: 2,377,515.00 · Class: 4.9%

  • MPM BioVentures 2014 (B), L.P.Reported CIK 0001609493

    Shares: 158,577.00 · Class: 0.3%

  • MPM Asset Management Investors BV2014 LLCReported CIK 0001609495

    Shares: 81,832.00 · Class: 0.2%

  • UBS Oncology Impact Fund L.P.Reported CIK 0001691428

    Shares: 1,965,659.00 · Class: 4.0%

  • MPM BioVentures 2014 GP LLCReported CIK 0001765091

    Shares: 2,536,092.00 · Class: 5.2%

  • MPM BioVentures 2014 LLCReported CIK 0001765021

    Shares: 2,617,924.00 · Class: 5.4%

  • Oncology Impact Fund (Cayman) Management L.P.Reported CIK 0001721036

    Shares: 1,965,659.00 · Class: 4.0%

  • MPM BioImpact LLCReported CIK 0001687078

    Shares: 1,965,659.00 · Class: 4.0%

  • ANSBERT GADICKEReported CIK 0001134655

    Shares: 5,481,539.00 · Class: 11.3%

  • LUKE EVNINReported CIK 0001134657

    Shares: 3,515,880.00 · Class: 7.2%

  • Todd FoleyReported CIK 0001473930

    Shares: 2,617,924.00 · Class: 5.4%

  • MPM ASSET MANAGEMENT LLCReported CIK 0001263048

    Shares: 376,471.00 · Class: 0.8%

  • MPM ONCOLOGY INNOVATIONS FUND LPReported CIK 0001719960

    Shares: 521,485.00 · Class: 1.1%

  • MPM Oncology Innovations Fund GP LLCReported CIK 0001857903

    Shares: 521,485.00 · Class: 1.1%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001231919-25-000511
Form type
SCHEDULE 13D/A
Filer
MPM BioVentures 2014, L.P.
CIK
CIK 1609492
Filed
Nov 17, 2025
Reporting period
Nov 13, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub